Telix

QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER

Retrieved on: 
화요일, 4월 16, 2024
Agreement, TLX, OTCQB, ASX, Plan, Reverse stock split, Telix, Common stock, Information, QSAM, Security (finance)

Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”) pursuant to which Telix will acquire QSAM (the “Merger”).

Key Points: 
  • Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”) pursuant to which Telix will acquire QSAM (the “Merger”).
  • On April 15, 2024, the Board of Directors of QSAM unanimously approved that the reverse stock split ratio be 1-for-2,000 such that once the reverse stock split goes into effect, every holder of Common Stock of the Company shall receive one share of Common Stock for every 2,000 shares of Common Stock held (the “Reverse Stock Split”).
  • On February 7, 2024, a majority of the voting shareholders of QSAM approved the reverse stock split and granted the Board the discretion to adopt the ratio prior to the closing of the Merger, which ratio the Board has adopted and is announcing today.
  • QSAM shareholders are encouraged to review the Information Statement for further information about the Merger and the Reverse Stock Split, which can be found on the SEC Edgar database: QSAM Definitive Information Statement .

EQS-News: Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty

Retrieved on: 
수요일, 4월 10, 2024
Diagnosis, Telix, Biologics license application, PET, Research, Sale, Multiple myeloma, Spacecraft, HPHA, ADC, USD, Positron emission tomography, Pharmaceutical industry

Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the formal closing of the royalty purchase agreement with HealthCare Royalty (HCRx) for Zircaix®, signed earlier this month.

Key Points: 
  • Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the formal closing of the royalty purchase agreement with HealthCare Royalty (HCRx) for Zircaix®, signed earlier this month.
  • Dr. George Badescu, Chief Business Officer at Heidelberg Pharma, said: “The funding from the royalty purchase agreement with HealthCare Royalty is enabling us to further advance Heidelberg Pharma’s leading expertise in the field of ADC research and development.
  • The upfront payment strengthens the Company’s liquidity, and along with future anticipated payments, should extend our cash runway.
  • The funds will be used to advance the expansion of our ADC pipeline including our preclinical projects HDP-102, HDP-103 and HDP-201.”

EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

Retrieved on: 
수요일, 3월 13, 2024
Morgan Stanley, Annual report, FDA, Food, Spacecraft, Sale, BLA, ADC, Telix, CAIX, McDermott Will & Emery, Patient, Diagnosis, HPHA, Phase, PET, Positron emission tomography, Pharmaceutical industry

Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.

Key Points: 
  • Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.
  • Key terms of the agreement between Heidelberg Pharma and HCRx:
    Following the receipt by HCRx of a maximum cumulative amount, royalty payments will revert to Heidelberg Pharma and HCRx will receive a low single digit royalty tail percentage thereafter
    Prof. Dr. Andreas Pahl, Chief Executive Officer at Heidelberg Pharma, commented: “We are delighted to partner with HealthCare Royalty.
  • This agreement will provide us with a non-dilutive financing based on expected royalty payments from the worldwide sales of ZircaixTM.
  • Heidelberg Pharma will hold a conference call on 25 March 2024 with the publication of the Annual Report.

QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee

Retrieved on: 
화요일, 11월 14, 2023
Acquisition, OTCQB, TLX, QSAM, FDA, Nuclear pharmacy, ASX, Orphan drug, Contingent value rights, Term sheet, Commercial property, Telix

Upon signing of the Term Sheet, Telix has agreed to pay the Company a US$2 million Pre-Closing Collaboration and Option Fee (the “Collaboration Fee”) to advance the Company’s development efforts based on mutually agreed goals and to provide sixty days of exclusivity pending completion of diligence and execution of a definitive acquisition agreement.

Key Points: 
  • Upon signing of the Term Sheet, Telix has agreed to pay the Company a US$2 million Pre-Closing Collaboration and Option Fee (the “Collaboration Fee”) to advance the Company’s development efforts based on mutually agreed goals and to provide sixty days of exclusivity pending completion of diligence and execution of a definitive acquisition agreement.
  • If the Acquisition does not close, the Collaboration Fee will be converted to Company common stock at a price of 6.70 per share.
  • Dr. C. Richard Piazza, QSAM’s Executive Chairman and co-Founder, stated, “We are thrilled to commence working with Telix by virtue of the Collaboration Fee to advance our technology and pursue a definitive agreement leading to the acquisition of QSAM by Telix.
  • With CycloSam® we plan to leverage Telix’s extensive experience and success in distributing short-life radiopharmaceuticals using a cold kit product from a nuclear pharmacy.

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

Retrieved on: 
월요일, 11월 13, 2023
Food and Drug Administration, Radiation, Euronext Growth, Food, Robotics, TLX, Disease, Surgeon, Urology, Mauna Kea Technologies, Patient, Mauna Kea, Medicine, FDA, ASX, Molecular imaging, Iris, Cancer, Partnership, CLE, AI, VWAP, Medical imaging, Security (finance), Telix

Telix's investment in Mauna Kea will further support the development of advanced imaging techniques for minimally invasive (laparoscopic and robotic) surgery, with a specific focus on urologic oncology.

Key Points: 
  • Telix's investment in Mauna Kea will further support the development of advanced imaging techniques for minimally invasive (laparoscopic and robotic) surgery, with a specific focus on urologic oncology.
  • Mauna Kea is a leading medical device company pioneering the development of real-time intraoperative visualisation of cancer tissue during surgery.
  • Mauna Kea's Cellvizio confocal laser endomicroscopy (CLE) in vivo cellular imaging platform has received U.S. Food and Drug Administration (FDA) approval and is CE Marked for a range of applications.
  • Following closing (on 17 November 2023), Telix will own 19.33% of the share capital and 19.01% of the voting rights of Mauna Kea.

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

Retrieved on: 
월요일, 11월 13, 2023
Food and Drug Administration, Radiation, Euronext Growth, Food, Robotics, TLX, Disease, Surgeon, Urology, Mauna Kea Technologies, Patient, Mauna Kea, Medicine, FDA, ASX, Molecular imaging, Iris, Cancer, Partnership, CLE, AI, VWAP, Medical imaging, Security (finance), Telix

Telix's investment in Mauna Kea will further support the development of advanced imaging techniques for minimally invasive (laparoscopic and robotic) surgery, with a specific focus on urologic oncology.

Key Points: 
  • Telix's investment in Mauna Kea will further support the development of advanced imaging techniques for minimally invasive (laparoscopic and robotic) surgery, with a specific focus on urologic oncology.
  • Mauna Kea is a leading medical device company pioneering the development of real-time intraoperative visualisation of cancer tissue during surgery.
  • Mauna Kea's Cellvizio confocal laser endomicroscopy (CLE) in vivo cellular imaging platform has received U.S. Food and Drug Administration (FDA) approval and is CE Marked for a range of applications.
  • Following closing (on 17 November 2023), Telix will own 19.33% of the share capital and 19.01% of the voting rights of Mauna Kea.

EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business

Retrieved on: 
목요일, 7월 13, 2023
State University of New York, AACR, EAP, GCC, Half-life, HPHA, ATAC, SRC, Binghamton University, Multiple myeloma, Clinical trial, State university system, Bone marrow, Cancer, American Association for Cancer Research, FSE, Magenta, Research, ATACS, Sale, Spanish mythology, Amanitin, Data analysis, CAIX, Patient, Antibody-drug conjugate, Microsoft Access, Marketing, CFO, Management, Ethics, ADC, Eli Lilly and Company, Depreciation, Spacecraft, Phase, FDA, Therapy, Market Access Program, Safety, Disease, Pharmaceutical industry, Vaccine, Fine chemical, Generic drug, Cryptocurrency, Telix, Emergence

Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).

Key Points: 
  • Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).
  • HDP-101 (BCMA-ATAC) program: Heidelberg Pharma presented preliminary safety data from the clinical trial with HDP-101.
  • The Heidelberg Pharma Group (Heidelberg Pharma) – comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH – reports consolidated figures.
  • The full-year financial guidance issued on 24 March 2023 for the Heidelberg Pharma Group is confirmed at this time.

New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC

Retrieved on: 
월요일, 6월 26, 2023
Society, University, SNMMI, Gland, Molecular imaging, Society of Nuclear Medicine and Molecular Imaging, ASX, Research, TLX, Lung, Renal cell carcinoma, Nuclear medicine, Patient, Lymph, Liver, CDT, UCLA, Pharmacology, Phase, Medical imaging, Telix, MD

New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting, and for staging and informing treatment decisions.

Key Points: 
  • New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting, and for staging and informing treatment decisions.
  • TLX250-CDx PET/CT detected more lesions in liver and bone than diagnostic CT imaging alone.
  • Data presented here in Chicago on extrarenal lesions demonstrates potential utility of TLX250-CDx for staging and monitoring high risk patients where there is a great deal of interest from the clinician community."
  • Telix is in the process of implementing an expanded access program in the United States and establishing named patient programs for TLX250-CDx in Europe.

New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC

Retrieved on: 
월요일, 6월 26, 2023
Society, University, SNMMI, Gland, Molecular imaging, Society of Nuclear Medicine and Molecular Imaging, ASX, Research, TLX, Lung, Renal cell carcinoma, Nuclear medicine, Patient, Lymph, Liver, CDT, UCLA, Pharmacology, Phase, Medical imaging, Telix, MD

New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting, and for staging and informing treatment decisions.

Key Points: 
  • New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting, and for staging and informing treatment decisions.
  • TLX250-CDx PET/CT detected more lesions in liver and bone than diagnostic CT imaging alone.
  • Data presented here in Chicago on extrarenal lesions demonstrates potential utility of TLX250-CDx for staging and monitoring high risk patients where there is a great deal of interest from the clinician community."
  • Telix is in the process of implementing an expanded access program in the United States and establishing named patient programs for TLX250-CDx in Europe.

Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI

Retrieved on: 
목요일, 6월 22, 2023
Newton, DNA, Society, SNMMI, PSMA, Molecular imaging, La Trobe University, Society of Nuclear Medicine and Molecular Imaging, IX, ASX, Research, TLX, Renal cell carcinoma, Nuclear medicine, Guideline, Patient, Annual general meeting, Telix, Merck, FDA, TARGET, Prostate cancer, Vaccine, Medical imaging, MD

Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118 ) will be delivered by Jeremie Calais, MD in an oral presentation.

Key Points: 
  • Further data from Telix's completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118 ) will be delivered by Jeremie Calais, MD in an oral presentation.
  • SNMMI 2023 will also feature presentations on Telix's lutetium-based, antibody-directed prostate cancer therapy program, ProstACT, and the Company's FDA-approved, gallium-based prostate cancer imaging agent, Illuccix®, where PSMA imaging with positron emission tomography (PSMA-PET) continues to be a focus for the nuclear medicine and molecular imaging community.
  • Alongside further data from the highly successful Phase III ZIRCON study in kidney cancer imaging, we are excited to present latest updates from our ProstACT SELECT and TARGET studies as this program builds momentum into the ProstACT GLOBAL study.
  • And last – but by no means least – our approved prostate cancer imaging agent, Illuccix, will feature on the program as part of lifecycle management.